全球胸苷酸合酶抑制剂药物市场 - 行业趋势和 2029 年预测

市场分析与洞察全球胸苷酸合酶抑制剂药物市场

胸苷酸合酶抑制剂药物市场预计将在 2022-2029 年的预测期内实现市场增长。Data Bridge Market Research 分析称，在上述预测期内，市场复合年增长率将达到 6%。

胸苷酸合酶抑制剂是一种通过抑制 DNA 合成来阻止肿瘤细胞发展的药物。它正在被研究作为一种癌症治疗方法。胸苷酸合酶 (TS) 催化叶酸依赖性酶中 2'-脱氧尿苷-5'-单磷酸盐的还原甲基化为 2'-脱氧胸苷-5'-单磷酸盐。由于该系统是 2'-脱氧胸苷-5'-三磷酸盐的唯一细胞内从头来源，因此 TS 是癌症治疗的重要靶点。

全球癌症发病率的上升将成为胸苷酸合酶抑制剂药物市场扩张的主要驱动力。此外，管道研究数量的激增和医疗支出的增加是扩大胸苷酸合酶抑制剂药物市场的因素。生活方式的改变和意识的提高等其他因素将对市场增长率产生积极影响。此外，医疗技术的进步、政府资金的增加和可支配收入水平的提高是提高胸苷酸合酶抑制剂药物市场增长率的因素。影响市场增长率的另一个重要因素是老年人口的增加。此外，全球制药公司的集中度不断提高也将促进市场的增长。

Moreover, the rise in the research and development activities, ongoing clinical trials and emerging new markets will provide beneficial opportunities for the thymidylate synthase inhibitor drugs market in the forecast period of 2022-2029. Also, high unmet need of current treatment and developments in healthcare technology will escalate the growth rate of market in future.

However, high cost associated with drugs and lack of infrastructure in low-income countries will impede the growth rate of market. Additionally, adverse effects linked with chemotherapies will hinder the market growth. Also, the dearth of awareness regarding health in many under-developed countries will further challenge the market in the forecast period mentioned above.

This thymidylate synthase inhibitor drugs market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the thymidylate synthase inhibitor drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Thymidylate Synthase Inhibitor Drugs Market Scope and Market Size

The thymidylate synthase inhibitor drugs market is segmented on the basis of drug type, application, dosage form, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

• On the basis of drug type, the thymidylate synthase inhibitor drugs market is segmented into raltitrexed, pemetrexed, nolatrexed and others.
• On the basis of application, the thymidylate synthase inhibitor drugs market is segmented into non-small cell lung cancer (NSCLC), mesothelioma (MPM) and others.
• On the basis of dosage form, the thymidylate synthase inhibitor drugs market is segmented into injection, tablets and others.
• On the basis of route of administration, the thymidylate synthase inhibitor drugs market is segmented into oral, intravenous and others.
• On the basis of end-users, the thymidylate synthase inhibitor drugs market is segmented into clinic, hospital and others.

The thymidylate synthase inhibitor drugs market is also segmented on the basis of distribution channel into hospital pharmacy, retail pharmacy and online pharmacy.

Thymidylate Synthase Inhibitor Drugs Market Country Level Analysis

Thymidylate synthase inhibitor drugs market is analyzed and market size information is provided by the country, drug type, application, dosage form, route of administration, end-users and distribution channel as referenced above.

The countries covered in the thymidylate synthase inhibitor drugs market report are the U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa.

North America dominates the thymidylate synthase inhibitor drugs market due to the presence of major key players, high disposable income and well-developed healthcare infrastructure in this region. Asia-Pacific is expected to grow during the forecast period of 2022-2029 due to the increasing research and development activities, surging prevalence of chronic diseases and growing government support in this region.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

Thymidylate synthase inhibitor drugs market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Global Thymidylate Synthase Inhibitor Drugs Market Share Analysis

胸苷酸合酶抑制剂药物市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、公司优势和劣势、产品发布、临床试验渠道、产品批准、专利、产品宽度和广度、应用优势、技术生命线曲线。以上提供的数据点仅与公司对胸苷酸合酶抑制剂药物市场研究的关注有关。

胸苷酸合酶抑制剂药物市场的一些主要参与者包括 Teva Pharmaceutical Industries Ltd.、Fresenius Kabi India Pvt. Ltd.、Cadila Pharmaceuticals、Eli Lilly and Company、Novartis AG、Amgen Inc.、AstraZeneca、Sanofi、Bristol-Myers Squibb Company、Merck & Co., Inc.、AbbVie Inc.、F. Hoffmann-La Roche Ltd.、Johnson & Johnson Private Limited、Mylan NV、Abbott、Pfizer Inc.、Accord Healthcare、GlaxoSmithKline plc、Sun Pharmaceutical Industries Ltd.、Bayer AG 和 Baxter 等。

SKU-67594